Kraepelinian dichotomy

The Kraepelinian dichotomy is the division of the major endogenous psychoses into the disease concepts of dementia praecox, which was reformulated as schizophrenia by Eugen Bleuler by 1908,^[1][2] and manic-depressive psychosis, which has now been reconceived as bipolar disorder.^[3] This division was formally introduced in the sixth edition of Emil Kraepelin's psychiatric textbook Psychiatrie. Ein Lehrbuch für Studierende und Aerzte, published in 1899.^[3] It has been highly influential on modern psychiatric classification systems, the DSM and ICD, and is reflected in the taxonomic separation of schizophrenia from affective psychosis.^[4] However, there is also a diagnosis of schizoaffective disorder to cover cases that seem to show symptoms of both.^[5]

The Kraepelinian system and the modern classification of psychoses are ultimately derived from the insights of Karl Kahlbaum.^[6] In 1863 the Prussian psychiatrist published his habilitation which was entitled, Die Gruppierung der psychischen Krankheiten (The Classification of Psychiatric Diseases).^[7] In this text he reviewed the then heterogeneous state of medical taxonomies of mental illness and enumerated the existence of some thirty such nosologies from the early seventeenth-century until the mid-nineteenth-century.^[8] The major contribution of his published dissertation, which is still the foundation of modern psychiatric nosology,^[8] was to first formulate the clinical method for the classification of psychosis by symptom, course and outcome.^[9]

Kahlbaum also differentiated between two major groups of mental illnesses which he termed vecordia and vesania.^[8]

Emil Kraepelin first introduced his proposed dichotomy between the endogenous psychoses of manic-depressive illness and dementia praecox during a public lecture in Heidelberg, Germany on 27 November 1898.^[10]

Central to Kraepelin’s theory was the idea that the longitudinal course of an illness was more reliable, as compared to cross-sectional symptom presentation, when it came to classification. Central to this shift was Kraepelin’s fifth edition of Psychiatrie (1896), written under the influence of Karl Ludwig Kahlbaum. In this work, he moved away from clinical syndromes and classified psychiatric diagnoses by progression of disease.

Dementia praecox itself was characterized as disordered intellectual functioning with progressive deterioration and no hopes of recovery. On the other hand, manic-depressive illness was considered a disorder of affect, with periods of exacerbation and remission, and some accounts of complete recovery.

Though Kraepelin was a proponent of this theory, he recognized the boundary was not clear. Near the end of his career, in his 1912 introduction to clinical psychiatry Kraepelin did not define dementia praecox solely by its chronic course and poor outcomes. In fact, he acknowledged remission and full recovery might be possible (similar to manic-depressive illness), and instead focused on how bizarre delusions and passive symptoms are defining clinical characteristics of dementia praecox.

Later analysis indicated that Kraepelin’s theory was based on the clinical population he primarily worked with, those with long inpatient stays. This skew in population and therefore severity, likely led him to overestimate the progressive decline in dementia praecox. Eugen Bleuler, who later coined the term schizophrenia, noted that not all patients had a progressive decline, a perspective that broadened the diagnosis from Kraepelin’s original formulation.

In fact, later statistical analysis of cases Kraepelin and collaborators studied in 1908 at a Munich clinic found a sampling bias. As he analyzed 53 dementia praecox cases, and 134 manic-depressive insanity cases, it was suggested that his concept of dementia praecox had narrow clinical criteria compared to schizophrenia, and that his understanding of manic-depressive illness likely included cases characterized as schizoaffective disorder.

In the last century, clinical work in psychiatry has proceeded under the assumption that schizophrenia and bipolar disorder are distinct entities with separate disease processes and treatment. However, many individuals with severe psychiatric illness present with both mood and psychotic symptoms. During the 1980’s, the reliability of the diagnostic criteria was challenged, though it was never abandoned.

Some researchers have proposed that functional psychoses are better understood on a spectrum. According to Craddock and Owen, the continuum extends from unipolar depression, bipolar affective, schizoaffective, to schizophrenia with increasing frequency of neuropsychological deficit. Empirical work has produced mixed results, studies using the schizo-bipolar scale find that while the majority of cases are near the poles, about 45% of cases are on the continuum, indicating no clear dichotomy.

A 2009 study by Lichtenstein examined more than 2 million families in Sweden and found that first-degree relatives of individuals with either schizophrenia or bipolar disorder, were at increased risk of either disorder. Also in 2009, the International Schizophrenia Consortium shared results from a genome-wide association study that confirmed overlap of polygenic variation between the two diagnoses.

Additionally, prenatal and immunological dysfunction have also been identified as risk factors for both diagnoses, with some gestational exposure present in both and specific to one.

The dichotomy can be seen in the DSM’s taxonomic separation of schizophrenia from affective psychosis, with schizoaffective disorder covering cases that show symptoms of both. Within the DSM-5 and ICD-10 framework, schizoaffective disorder appears to function as a “not otherwise specified: category, as it is used when clinical presentation does not nearly match either schizophrenia or bipolar disorder.

Pharmacology has offered evidence that both supports and is against the dichotomy. The use of mood stabilizers, such as lithium, valproate, and carbamazepine, specifically to treat bipolar disorder supports the distinction. On the other hand, the therapeutic benefit of antipsychotics, like olanzapine across both conditions, speaks against it. Critics have argued that the categorical framework impedes treatment research, as cases with both psychotic and bipolar features are often excluded from trials or combined with other diagnostic classifications.

Several other nosological frameworks have been shared. Some examples include Crow’s continuum model, Angst and Akiskal, Marnero’s focus on schizoaffective illness, and the polychotomous Leonhardian diagnostic system. Other perspectives have also been advocated for, including a dimensional approach. In this theory, continuous symptoms are influenced by two major factors: a neurodevelopmental impairment factor and an affective-socially reactive factor. The neurodevelopmental impairment factor is typically associated with negative psychotic symptoms, family history of schizophrenia, and poor outcomes. Alternatively, the affective-socially reactive factor is associated with positive psychotic symptoms, family history or affective disorder, and better outcomes.

A substantial amount of genetic evidence suggests that schizophrenia and bipolar disorder share an overlap in genetic risk, implying similar aspects of pathogenesis, which would be inconsistent with Kraeplin’s theory. As of 2026, the Kraepelinian dichotomy is still considered partly valid though results from studies indicate no clear consensus.

• Comparison of bipolar disorder and schizophrenia
• History of bipolar disorder
• History of schizophrenia